Compare Nasdaq Inc (NDAQ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Pfizer Inc — how do they compare? Nasdaq Inc trades at $92.99 (market cap $51.63B), while Pfizer Inc trades at $28.13 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 3.1× Nasdaq Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 125 Days and Pfizer Inc for 158 Days on average.
| NDAQ | PFE | |
|---|---|---|
Market Cap | $51.63B | $158.56B |
Volume | 2,668,175 | 44,138,282 |
Sector | Financials | Health |
52-Week High | $100.98 | $29.02 |
52-Week Low | $76.85 | $23.67 |
Typical Hold Time | 125 Days | 158 Days |
Enterprise Value | $58.09B | $210.06B |
Dividend Yield | 1.26% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq Inc. (NDAQ) trades at $91.93, down 0.37% on the day, with strong fundamentals including 2025 revenue of $8.26B and net income of $1.79B. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $1.02 EPS. Technical indicators show a bearish overall signal despite bullish moving averages, with key support at $90 and resistance at $92-94.
NDAQ presents a compelling investment case with 61% analyst buy ratings and a $110.43 consensus price target, representing 20% upside. Strong profitability metrics (22.5% net margin, 16.5% ROE) and growing Financial Technology business offset technical weakness. Risks include market volatility exposure and competitive pressures in exchange services.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
